These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 15083595

  • 1. Targets for modulation of fatty acid oxidation in the heart.
    Lopaschuk GD.
    Curr Opin Investig Drugs; 2004 Mar; 5(3):290-4. PubMed ID: 15083595
    [Abstract] [Full Text] [Related]

  • 2. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation.
    Dyck JR, Cheng JF, Stanley WC, Barr R, Chandler MP, Brown S, Wallace D, Arrhenius T, Harmon C, Yang G, Nadzan AM, Lopaschuk GD.
    Circ Res; 2004 May 14; 94(9):e78-84. PubMed ID: 15105298
    [Abstract] [Full Text] [Related]

  • 3. Metabolic therapy for the treatment of ischemic heart disease: reality and expectations.
    Wang W, Lopaschuk GD.
    Expert Rev Cardiovasc Ther; 2007 Nov 14; 5(6):1123-34. PubMed ID: 18035928
    [Abstract] [Full Text] [Related]

  • 4. Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated?
    Lopaschuk GD.
    Coron Artery Dis; 2001 Feb 14; 12 Suppl 1():S8-11. PubMed ID: 11286307
    [Abstract] [Full Text] [Related]

  • 5. Targeting malonyl CoA inhibition of mitochondrial fatty acid uptake as an approach to treat cardiac ischemia/reperfusion.
    Ussher JR, Lopaschuk GD.
    Basic Res Cardiol; 2009 Mar 14; 104(2):203-10. PubMed ID: 19242641
    [Abstract] [Full Text] [Related]

  • 6. Cardiac energetics during ischaemia and the rationale for metabolic interventions.
    Stanley WC.
    Coron Artery Dis; 2001 Feb 14; 12 Suppl 1():S3-7. PubMed ID: 11286306
    [Abstract] [Full Text] [Related]

  • 7. [Myocardial metabolism abnormalities during ischemia and reperfusion].
    Argaud L, Ovize M.
    Arch Mal Coeur Vaiss; 2000 Jan 14; 93(1):87-90. PubMed ID: 11227723
    [Abstract] [Full Text] [Related]

  • 8. AMP-activated protein kinase control of energy metabolism in the ischemic heart.
    Lopaschuk GD.
    Int J Obes (Lond); 2008 Sep 14; 32 Suppl 4():S29-35. PubMed ID: 18719595
    [Abstract] [Full Text] [Related]

  • 9. The malonyl CoA axis as a potential target for treating ischaemic heart disease.
    Ussher JR, Lopaschuk GD.
    Cardiovasc Res; 2008 Jul 15; 79(2):259-68. PubMed ID: 18499682
    [Abstract] [Full Text] [Related]

  • 10. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase.
    Lopaschuk GD, Barr R, Thomas PD, Dyck JR.
    Circ Res; 2003 Aug 08; 93(3):e33-7. PubMed ID: 12869392
    [Abstract] [Full Text] [Related]

  • 11. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion.
    Wang P, Fraser H, Lloyd SG, McVeigh JJ, Belardinelli L, Chatham JC.
    J Pharmacol Exp Ther; 2007 Apr 08; 321(1):213-20. PubMed ID: 17202401
    [Abstract] [Full Text] [Related]

  • 12. Anti-anginal effects of partial fatty acid oxidation inhibitors.
    Lam A, Lopaschuk GD.
    Curr Opin Pharmacol; 2007 Apr 08; 7(2):179-85. PubMed ID: 17307396
    [Abstract] [Full Text] [Related]

  • 13. Improvement of the energy supply and contractile function in normal and ischemic rat hearts by dietary orotic acid.
    Pôrto LC, de Castro CH, Savergnini SS, Santos SH, Ferreira AV, Cordeiro LM, Sobrinho DB, Santos RA, de Almeida AP, Botion LM.
    Life Sci; 2012 Apr 09; 90(13-14):476-83. PubMed ID: 22285839
    [Abstract] [Full Text] [Related]

  • 14. Energetic myocardial metabolism and oxidative stress: let's make them our friends in the fight against heart failure.
    Scolletta S, Biagioli B.
    Biomed Pharmacother; 2010 Mar 09; 64(3):203-7. PubMed ID: 19954925
    [Abstract] [Full Text] [Related]

  • 15. [Modifications in myocardial energy metabolism in diabetic patients]].
    Grynberg A.
    Diabetes Metab; 2001 Nov 09; 27(5 Pt 2):S12-9. PubMed ID: 11910980
    [Abstract] [Full Text] [Related]

  • 16. Absence of malonyl coenzyme A decarboxylase in mice increases cardiac glucose oxidation and protects the heart from ischemic injury.
    Dyck JR, Hopkins TA, Bonnet S, Michelakis ED, Young ME, Watanabe M, Kawase Y, Jishage K, Lopaschuk GD.
    Circulation; 2006 Oct 17; 114(16):1721-8. PubMed ID: 17030679
    [Abstract] [Full Text] [Related]

  • 17. A novel partial fatty acid oxidation inhibitor decreases myocardial oxygen consumption and improves cardiac efficiency in demand-induced ischemic heart.
    Wu L, Belardinelli L, Fraser H.
    J Cardiovasc Pharmacol; 2008 Apr 17; 51(4):372-9. PubMed ID: 18427280
    [Abstract] [Full Text] [Related]

  • 18. Alterations in myocardial fatty acid metabolism contribute to ischemic injury in the diabetic.
    Lopaschuk GD.
    Can J Cardiol; 1989 Sep 17; 5(6):315-20. PubMed ID: 2676122
    [Abstract] [Full Text] [Related]

  • 19. Alterations in energy metabolism in cardiomyopathies.
    Taha M, Lopaschuk GD.
    Ann Med; 2007 Sep 17; 39(8):594-607. PubMed ID: 17934906
    [Abstract] [Full Text] [Related]

  • 20. Malonyl-CoA decarboxylase inhibition as a novel approach to treat ischemic heart disease.
    Lopaschuk GD, Stanley WC.
    Cardiovasc Drugs Ther; 2006 Dec 17; 20(6):433-9. PubMed ID: 17136490
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.